BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9930854)

  • 1. HIV-1 neutralizing antibodies: how full is the bottle?
    Moore JP; Burton DR
    Nat Med; 1999 Feb; 5(2):142-4. PubMed ID: 9930854
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
    Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
    J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodominant antigenic sites in primate immunodeficiency viruses and in vivo protection.
    Norrby E; Putkonen P; Albert J; Fenyö EM
    Biotechnol Ther; 1991; 2(1-2):21-9. PubMed ID: 1668984
    [No Abstract]   [Full Text] [Related]  

  • 7. Cowpox Helped Against Smallpox; Will the Goat Lentivirus (Caprine Arthritis Encephalitis Virus) Help Against HIV-1?
    Chebloune Y; Moussa M; Arrode-Brusés G; Gagnon J
    AIDS Res Hum Retroviruses; 2015 Jun; 31(6):577-8. PubMed ID: 25844817
    [No Abstract]   [Full Text] [Related]  

  • 8. AIDS vaccine development in primate models.
    Almond NM; Heeney JL
    AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine development: lessons learned to date.
    Putney SD
    Biotechnol Ther; 1991; 2(1-2):1-7. PubMed ID: 1726960
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigen presentation and related immunological aspects of HIV-1 vaccines.
    Steinman RM; Germain RN
    AIDS; 1998; 12 Suppl A():S97-112. PubMed ID: 9632991
    [No Abstract]   [Full Text] [Related]  

  • 12. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological responses to candidate AIDS vaccines.
    Graham BS
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S145-8. PubMed ID: 7865290
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
    Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
    Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of HIV/AIDS vaccines--1993.
    Weber J
    Ther Immunol; 1994 Apr; 1(2):95-100. PubMed ID: 7584488
    [No Abstract]   [Full Text] [Related]  

  • 20. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.